Pathophysiology of the aging kidney and therapeutic interventions

Hypertension Research

Volumn 35, Issue 12, 2012, Pages 1121-1128

  Kanasaki, Keizo ^a   Kitada, Munehiro ^a   Koya, Daisuke ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

fibrosis; Klotho; RAS; senescence; sirtuins

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIFIBROTIC AGENT; CALCITRIOL; CAPTOPRIL; CREATININE; ERYTHROPOIETIN; INSULIN; INULIN; KLOTHO PROTEIN; OSTEOGENIC PROTEIN 1; PIRFENIDONE; SIRTUIN 1; SODIUM; THR 123; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AGING; CREATININE CLEARANCE; FOCAL GLOMERULOSCLEROSIS; GLOMERULOSCLEROSIS; GLOMERULUS; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN RELEASE; KIDNEY; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FIBROSIS; NEPHRON; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; SODIUM EXCRETION; VASOCONSTRICTION;

AGING; ANIMALS; CALORIC RESTRICTION; ERYTHROPOIETIN; FIBROSIS; GLUCURONIDASE; HUMANS; INSULIN; KIDNEY; NEPHRONS; SIGNAL TRANSDUCTION; SIRTUIN 1; VITAMIN D;

EID: 84870818167     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.159     Document Type: Review

References (142)

1. RoseMR.Evolutionary Biology of Aging. Oxford University Press, New York, 1991.
2. Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG. The aging kidney. Kidney Int2008; 74: 710-720.
3. Epstein M. Aging and the kidney. J Am Soc Nephrol 1996; 7: 1106-1122.
4. Hoy WE, Douglas-Denton RN, Hughson MD, Cass A, Johnson K, Bertram JF.A stereological study of glomerular number and volume: preliminary findings in amultiracial study of kidneys at autopsy. Kidney Int Suppl 2003: S31-S37.
5. Anderson S, Brenner BM. Effects of aging on the renal glomerulus. Am J Med 1986;80: 435-442.
6. Thomas SE, Anderson S, Gordon KL, Oyama TT, Shankland SJ, Johnson RJ.Tubulointerstitial disease in aging: evidence for underlying peritubular capillarydamage, a potential role for renal ischemia. J Am Soc Nephrol 1998; 9: 231-242.
7. Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to age, kidneyweight, and body surface in normal man. Anat Rec 1992; 232: 194-201.
8. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renalfunction with age. J Am Geriatr Soc 1985; 33: 278-285.
9. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-spanextension by calorie restriction in Saccharomyces cerevisiae. Science 2000; 289:2126-2128.
10. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y,Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S,Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndromeresembling ageing. Nature 1997; 390: 45-51.
11. Fuiano G, Sund S, Mazza G, Rosa M, Caglioti A, Gallo G, Natale G, Andreucci M,Memoli B, De Nicola L, Conte G. Renal hemodynamic response to maximalvasodilating stimulus in healthy older subjects. Kidney Int 2001; 59: 1052-1058.
12. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinineclearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31:155-163.
13. Lindeman RD. Is the decline in renal function with normal aging inevitable? GeriatrNephrol Urol 1998; 8: 7-9.
14. Miller M. Hormonal aspects of fluid and sodium balance in the elderly. EndocrinolMetab Clin North Am 1995; 24: 233-253.
15. Ungar A, Cristofari C, Torrini M, Di Serio C, Cantini C, Vallotti B, La Cava G, CastellaniS, Masotti G. Changes in renal autacoids in aged human hypertensives. J PhysiolPharmacol 2000; 51(Pt 1): 619-630.
16. Terragno NA, Terragno DA, McGiff JC. Contribution of prostaglandins to the renalcirculation in conscious, anesthetized, and laparotomized dogs. Circ Res 1977; 40:590-595.
17. Esposito C, Plati A, Mazzullo T, Fasoli G, De Mauri A, Grosjean F, Mangione F,Castoldi F, Serpieri N, Cornacchia F, Dal Canton A. Renal function and functionalreserve in healthy elderly individuals. J Nephrol 2007; 20: 617-625.
18. Field TS, Gurwitz JH, Glynn RJ, Salive ME, Gaziano JM, Taylor JO, Hennekens CH.The renal effects of nonsteroidal anti-inflammatory drugs in older people: findingsfrom the Established Populations for Epidemiologic Studies of the Elderly. J AmGeriatr Soc 1999; 47: 507-511.
19. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologicfoundations and clinical implications. Am J Med 1999; 106: 13S-24S.
20. Mulkerrin E, Epstein FH, Clark BA. Reduced renal response to low-dose dopamineinfusion in the elderly. J Gerontol A Biol Sci Med Sci 1995; 50: M271-M275.
21. Morrissey PE, Yango AF. Renal transplantation: older recipients and donors. ClinGeriatr Med 2006; 22: 687-707.
22. Musch W, Verfaillie L, Decaux G. Age-related increase in plasma urea level anddecrease in fractional urea excretion: clinical application in the syndrome ofinappropriate secretion of antidiuretic hormone. Clin J Am Soc Nephrol 2006; 1:909-914.
23. Giannelli SV, Patel KV, Windham BG, Pizzarelli F, Ferrucci L, Guralnik JM. Magnitudeof underascertainment of impaired kidney function in older adults with normal serumcreatinine. J Am Geriatr Soc 2007; 55: 816-823.
24. Epstein M, Hollenberg NK. Age as a determinant of renal sodium conservation innormal man. J Lab Clin Med 1976; 87: 411-417.
25. Wang H, Zhang M, Wang H. Renal sodium transport in heathy elderly and elderlyhypertension. Geriatr Nephrol Urol 1996; 6: 13-19.
26. Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: drugs exacerbateimpaired potassium homeostasis. J Gen Intern Med 1997; 12: 646-656.
27. Rowe JW, Shock NW, DeFronzo RA. The influence of age on the renal response towater deprivation in man. Nephron 1976; 17: 270-278.
28. Sands JM. Urine-concentrating ability in the aging kidney. Sci Aging KnowledgeEnviron 2003; 2003: PE15.
29. ElDesoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther2007; 14: 488-498.
30. Toprak O. Risk markers for contrast-induced nephropathy. Am J Med Sci 2007; 334:283-290.
31. Pucelikova T, Dangas G, Mehran R. Contrast-induced nephropathy. CatheterCardiovasc Interv 2008; 71: 62-72.
32. Schmitt R, Cantley LG. The impact of aging on kidney repair. Am J Physiol RenalPhysiol 2008; 294: F1265-F1272.
33. Eisenstaedt R, Penninx BW, Woodman RC. Anemia in the elderly: currentunderstanding and emerging concepts. Blood Rev 2006; 20: 213-226.
34. Ble A, Fink JC, Woodman RC, Klausner MA, Windham BG, Guralnik JM, Ferrucci L.Renal function, erythropoietin, and anemia of older persons: the InCHIANTI study.Arch Intern Med 2005; 165: 2222-2227.
35. Ershler WB, Sheng S, McKelvey J, Artz AS, Denduluri N, Tecson J, Taub DD, Brant LJ,Ferrucci L, Longo DL. Serum erythropoietin and aging: a longitudinal analysis. J AmGeriatr Soc 2005; 53: 1360-1365.
36. Carpenter MA, Kendall RG, O'Brien AE, Chapman C, Sebastian JP, Belfield PW,Norfolk DR. Reduced erythropoietin response to anaemia in elderly patients withnormocytic anaemia. Eur J Haematol 1992; 49: 119-121.
37. Ferrucci L, Guralnik JM, Bandinelli S, Semba RD, Lauretani F, Corsi A, Ruggiero C,Ershler WB, Longo DL. Unexplained anaemia in older persons is characterised by lowerythropoietin and low levels of pro-inflammatory markers. Br J Haematol 2007; 136:849-855.
38. Kario K, Matsuo T, Kodama K, Nakao K, Asada R. Reduced erythropoietin secretion insenile anemia. Am J Hematol 1992; 41: 252-257.
39. Gallagher JC, Rapuri P, Smith L. Falls are associated with decreased renal functionand insufficient calcitriol production by the kidney. J Steroid Biochem Mol Biol 2007;103: 610-613.
40. Dukas L, Schacht E, Stahelin HB. In elderly men and women treated for osteoporosisa low creatinine clearance of o65 ml/min is a risk factor for falls and fractures.Osteoporos Int 2005; 16: 1683-1690.
41. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential.Endocr Rev 1998; 19: 608-624.
42. Akmal M, Massry SG, Goldstein DA, Fanti P, Weisz A, DeFronzo RA. Role ofparathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest1985; 75: 1037-1044.
43. Massry SG, Fadda GZ, Zhou XJ, Chandrasoma P, Cheng L, Filburn CR. Impairedinsulin secretion of aging: role of renal failure and hyperparathyroidism. Kidney Int1991; 40: 662-667.
44. Basu R, Breda E, Oberg AL, Powell CC, Dalla Man C, Basu A, Vittone JL, Klee GG,Arora P, Jensen MD, Toffolo G, Cobelli C, Rizza RA. Mechanisms of the age-associateddeterioration in glucose tolerance: contribution of alterations in insulin secretion,action, and clearance. Diabetes 2003; 52: 1738-1748.
45. Kosch M, Barenbrock M, Kisters K, Rahn KH, Hausberg M. Relationship betweenmuscle sympathetic nerve activity and large artery mechanical vessel wall propertiesin renal transplant patients. J Hypertens 2002; 20: 501-508.
46. Grassi G, Calhoun DA. Sympathetic-vascular interactions: further evidence in kidneytransplantation. J Hypertens 2002; 20: 379-381.
47. Zhou XJ, Saxena R, Liu Z, Vaziri ND, Silva FG. Renal senescence in 2008: progressand challenges. Int Urol Nephrol 2008; 40: 823-839.
48. Johnson S, Rishi R, Andone A, Khawandi W, Al-Said J, Gletsu-Miller N, Lin E,Baumgarten DA, O'Neill WC. Determinants and functional significance of renalparenchymal volume in adults. Clin J Am Soc Nephrol 2011; 6: 70-76.
49. Herts BR, Sharma N, Lieber M, Freire M, Goldfarb DA, Poggio ED. Estimatingglomerular filtration rate in kidney donors: a model constructed with renal volumemeasurements from donor CT scans. Radiology 2009; 252: 109-116.
50. Jeon HG, Lee SR, Joo DJ, Oh YT, Kim MS, Kim YS, Yang SC, Han WK. Predictors ofkidney volume change and delayed kidney function recovery after donor nephrectomy.J Urol 2010; 184: 1057-1063.
51. Rule AD, Amer H, Cornell LD, Taler SJ, Cosio FG, Kremers WK, Textor SC, Stegall MD.The association between age and nephrosclerosis on renal biopsy among healthyadults. Ann Intern Med 2010; 152: 561-567.
52. Goyal VK. Changes with age in the human kidney. Exp Gerontol 1982; 17: 321-331.
53. Abdi R, Slakey D, Kittur D, Racusen LC. Heterogeneity of glomerular size in normaldonor kidneys: impact of race. Am J Kidney Dis 1998; 32: 43-46.
54. McLachlan MS. The ageing kidney. Lancet 1978; 2: 143-145.
55. Rule AD, Semret MH, Amer H, Cornell LD, Taler SJ, Lieske JC, Melton 3rd LJ,Stegall MD, Textor SC, Kremers WK, Lerman LO. Association of kidney function andmetabolic risk factors with density of glomeruli on renal biopsy samples from livingdonors. Mayo Clin Proc 2011; 86: 282-290.
56. Zheng F, Plati AR, Potier M, Schulman Y, Berho M, Banerjee A, Leclercq B, Zisman A,Striker LJ, Striker GE. Resistance to glomerulosclerosis in B6 mice disappears aftermenopause. Am J Pathol 2003; 162: 1339-1348.
57. Bolton WK, Sturgill BC. Spontaneous glomerular sclerosis in aging Sprague-Dawleyrats. II. Ultrastructural studies. Am J Pathol 1980; 98: 339-356.
58. Wiggins JE. Aging in the Glomerulus. J Gerontol A Biol Sci Med Sci. (e-pub ahead ofprint 25 July 2012; doi:10.1093/gerona/gls157).
59. Stojanović V, C? ukuranović R, Jovanović I, Vasović L, Vlajković S, Ugrenović S,Pavlović S, Dimitra L. The quantification of glomerular endothelial and mesangialcells during the human aging. Acta Fac Med Naiss 2004; 21: 65-71.
60. Wiggins JE, Goyal M, Sanden SK, Wharram BL, Shedden KA, Misek DE, Kuick RD,Wiggins RC. Podocyte hypertrophy, 'adaptation,' and 'decompensation' associatedwith glomerular enlargement and glomerulosclerosis in the aging rat: prevention bycalorie restriction. J Am Soc Nephrol 2005; 16: 2953-2966.
61. Ortmann J, Amann K, Brandes RP, Kretzler M, Munter K, Parekh N, Traupe T, LangeM, Lattmann T, Barton M. Role of podocytes for reversal of glomerulosclerosis andproteinuria in the aging kidney after endothelin inhibition. Hypertension 2004; 44:974-981.
62. Takazakura E, Sawabu N, Handa A, Takada A, Shinoda A, Takeuchi J. Intrarenalvascular changes with age and disease. Kidney Int 1972; 2: 224-230.
63. Tracy RE, Ishii T. What is 'nephrosclerosis'? Lessons from the US, Japan, and Mexico.Nephrol Dial Transplant 2000; 15: 1357-1366.
64. Tracy RE, Parra D, Eisaguirre W, Torres Balanza RA. Influence of arteriolarhyalinization on arterial intimal fibroplasia in the renal cortex of subjects in theUnited States, Peru, and Bolivia, applicable also to other populations. Am JHypertens 2002; 15: 1064-1073.
65. Darmady EM, Offer J, Woodhouse MA. The parameters of the ageing kidney. J Pathol1973; 109: 195-207.
66. Baert L, Steg A. Is the diverticulum of the distal and collecting tubules a preliminarystage of the simple cyst in the adult? J Urol 1977; 118: 707-710.
67. Tanaka T, Kato H, Kojima I, Ohse T, Son D, Tawakami T, Yatagawa T, Inagi R, Fujita T,Nangaku M. Hypoxia and expression of hypoxia-inducible factor in the aging kidney.J Gerontol A Biol Sci Med Sci 2006; 61: 795-805.
68. Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. CurrOpin Genet Dev 1998; 8: 588-594.
69. Nangaku M, Inagi R, Miyata T, Fujita T. Hypoxia and hypoxia-inducible factor in renaldisease. Nephron Exp Nephrol 2008; 110: e1-e7.
70. Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol 2007; 2: 145-173.
71. Kimura K, Iwano M, Higgins DF, Yamaguchi Y, Nakatani K, Harada K, Kubo A, Akai Y,Rankin EB, Neilson EG, Haase VH, Saito Y. Stable expression of HIF-1alpha intubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol2008; 295: F1023-F1029.
72. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y,Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH. Hypoxiapromotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymaltransition. J Clin Invest 2007; 117: 3810-3820.
73. Choudhury D, Levi M. Kidney aging-inevitable or preventable? Nat Rev Nephrol2011; 7: 706-717.
74. Weindruch R, Naylor PH, Goldstein AL, Walford RL. Influences of aging and dietaryrestriction on serum thymosin alpha 1 levels in mice. J Gerontol 1988; 43:B40-B42.
75. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM,Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R. Caloric restrictiondelays disease onset and mortality in rhesus monkeys. Science 2009; 325:201-204.
76. Liang F, Kume S, Koya D. SIRT1 and insulin resistance. Nat Rev Endocrinol 2009; 5:367-373.
77. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT,Gorospe M, de Cabo R, Sinclair DA. Calorie restriction promotes mammalian cellsurvival by inducing the SIRT1 deacetylase. Science 2004; 305: 390-392.
78. Kume S, Uzu T, Horiike K, Chin-Kanasaki M, Isshiki K, Araki S, Sugimoto T, HanedaM, Kashiwagi A, Koya D. Calorie restriction enhances cell adaptation to hypoxiathrough Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest2010; 120: 1043-1055.
79. Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, Czopik A, Steele AD, CroweH, Marmor S, Luo J, Gu W, Guarente L. SIRT1 transgenic mice show phenotypesresembling calorie restriction. Aging Cell 2007; 6: 759-767.
80. Sharma S, Anjaneyulu M, Kulkarni SK, Chopra K. Resveratrol a polyphenolicphytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006; 76:69-75.
81. Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A. Change in histone H3phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol inpreventing streptozotocin induced type I diabetic nephropathy. Free Radic Res 2008;42: 397-404.
82. Ding DF, You N, Wu XM, Xu JR, Hu AP, Ye XL, Zhu Q, Jiang XQ, Miao H, Liu C, Lu YB.Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK.Am J Nephrol 2010; 31: 363-374.
83. Kitada M, Kume S, Imaizumi N, Koya D. Resveratrol improves oxidative stress andprotects against diabetic nephropathy through normalization of Mn-SOD dysfunctionin AMPK/SIRT1-independent pathway. Diabetes 2011; 60: 634-643.
84. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, Garcia JA.Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsivedeacetylase sirtuin 1. Science 2009; 324: 1289-1293.
85. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient controlof glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005;434: 113-118.
86. Boily G, Seifert EL, Bevilacqua L, He XH, Sabourin G, Estey C, Moffat C,Crawford S, Saliba S, Jardine K, Xuan J, Evans M, Harper ME, McBurney MW. SirT1regulates energy metabolism and response to caloric restriction in mice. PLoS One2008; 3: e1759.
87. Jiang T, Wang XX, Scherzer P, Wilson P, Tallman J, Takahashi H, Li J, Iwahashi M,Sutherland E, Arend L, Levi M. Farnesoid X receptor modulates renal lipidmetabolism, fibrosis, and diabetic nephropathy. Diabetes 2007; 56: 2485-2493.
88. Wang XX, Jiang T, Shen Y, Adorini L, Pruzanski M, Gonzalez FJ, Scherzer P, Lewis L,Miyazaki-Anzai S, Levi M. The farnesoid X receptor modulates renal lipid metabolismand diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol RenalPhysiol 2009; 297: F1587-F1596.
89. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates andpositively regulates the nuclear receptor LXR. Mol Cell 2007; 28: 91-106.
90. Kemper JK, Xiao Z, Ponugoti B, Miao J, Fang S, Kanamaluru D, Tsang S, Wu SY,Chiang CM, Veenstra TD. FXR acetylation is normally dynamically regulated by p300and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 2009;10: 392-404.
91. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP,Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR,Rosenblatt KP, Kuro-o M. Suppression of aging in mice by the hormone Klotho.Science 2005; 309: 1829-1833.
92. Kuro-o M. Klotho and the aging process. Korean J Intern Med 2011; 26: 113-122.
93. Kuro-o M. A potential link between phosphate and aging-lessons from Klothodeficientmice. Mech Ageing Dev 2010; 131: 270-275.
94. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger ofpremature cardiovascular disease. J Intern Med 2010; 268: 456-467.
95. Kuro OM. Klotho in health and disease. Curr Opin Nephrol Hypertens 2012; 21:362-368.
96. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int2012; 82: 737-747.
97. Lan HY. Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J BiolSci 2011; 7: 1056-1067.
98. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl JMed 1994; 331: 1286-1292.
99. Miyazono KTGF. beta signaling by Smad proteins. Cytokine Growth Factor Rev 2000;11: 15-22.
100. Kanasaki M, Nagai T, Kitada M, Koya D, Kanasaki K. Elevation of the anti-fibroticpeptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficialeffect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair2011; 4: 25.
101. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S,Kawabata M, Heldin NE, Heldin CH, ten Dijke P. Identification of Smad7, a TGFbetainducibleantagonist of TGF-beta signalling. Nature 1997; 389: 631-635.
102. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, ChenS, McGowan TA, Sharma K. Long-term prevention of renal insufficiency, excess matrixgene expression, and glomerular mesangial matrix expansion by treatment withmonoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. ProcNatl Acad Sci USA 2000; 97: 8015-8020.
103. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG. Regulation ofconnective tissue growth factor activity in cultured rat mesangial cells and itsexpression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000; 11:25-38.
104. Huang XR, Chung AC, Wang XJ, Lai KN, Lan HY. Mice overexpressing latentTGF-beta1 are protected against renal fibrosis in obstructive kidney disease. Am JPhysiol Renal Physiol 2008; 295: F118-F127.
105. Huang XR, Chung AC, Zhou L, Wang XJ, Lan HY. Latent TGF-beta1 protects againstcrescentic glomerulonephritis. J Am Soc Nephrol 2008; 19: 233-242.
106. Meng XM, Huang XR, Chung AC, Qin W, Shao X, Igarashi P, Ju W, Bottinger EP, LanHY. Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am SocNephrol 2010; 21: 1477-1487.
107. Choi K, Lee K, Ryu SW, Im M, Kook KH, Choi C. Pirfenidone inhibits transforminggrowth factor-beta1-induced fibrogenesis by blocking nuclear translocation ofSmads in human retinal pigment epithelial cell line ARPE-19. Mol Vis 2012; 18:1010-1020.
108. RamachandraRao SP, Zhu Y, Ravasi T, McGowan TA, Toh I, Dunn SR, Okada S, ShawMA, Sharma K. Pirfenidone is renoprotective in diabetic kidney disease. J Am SocNephrol 2009; 20: 1765-1775.
109. Takakuta K, Fujimori A, Chikanishi T, Tanokura A, Iwatsuki Y, Yamamoto M, NakajimaH, Okada M, Itoh H. Renoprotective properties of pirfenidone in subtotallynephrectomized rats. Eur J Pharmacol 2010; 629: 118-124.
110. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S,Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, KoppJB. Pirfenidone for diabetic nephropathy. J AmSoc Nephrol 2011; 22: 1144-1151.
111. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renalfunction decline in patients with focal segmental glomerulosclerosis. Clin J Am SocNephrol 2007; 2: 906-913.
112. Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebratedevelopment. Genes Dev 1996; 10: 1580-1594.
113. Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and openquestions. Nephrol Dial Transplant 2006; 21: 568-573.
114. Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W,Affolter M, Vale WW, Izpisua Belmonte JC, Choe S. Structural basis of BMP signallinginhibition by the cystine knot protein Noggin. Nature 2002; 420: 636-642.
115. Merino R, Rodriguez-Leon J, Macias D, Ganan Y, Economides AN, Hurle JM. TheBMP antagonist Gremlin regulates outgrowth, chondrogenesis and programmed celldeath in the developing limb. Development 1999; 126: 5515-5522.
116. Wilkinson L, Kolle G, Wen D, Piper M, Scott J, Little M. CRIM1 regulates the rate ofprocessing and delivery of bone morphogenetic proteins to the cell surface. J BiolChem 2003; 278: 34181-34188.
117. Belo JA, Bachiller D, Agius E, Kemp C, Borges AC, Marques S, Piccolo S, De RobertisEM. Cerberus-like is a secreted BMP and nodal antagonist not essential for mousedevelopment. Genesis 2000; 26: 265-270.
118. Piccolo S, Sasai Y, Lu B, De Robertis EM. Dorsoventral patterning in Xenopus:inhibition of ventral signals by direct binding of chordin to BMP-4. Cell 1996; 86:589-598.
119. Yanagita M, Okuda T, Endo S, Tanaka M, Takahashi K, Sugiyama F, Kunita S,Takahashi S, Fukatsu A, Yanagisawa M, Kita T, Sakurai T. Uterine sensitizationassociatedgene-1 (USAG-1), a novel BMP antagonist expressed in the kidney,accelerates tubular injury. J Clin Invest 2006; 116: 70-79.
120. Lin J, Patel SR, Cheng X, Cho EA, Levitan I, Ullenbruch M, Phan SH, Park JM,Dressler GR. Kielin/chordin-like protein, a novel enhancer of BMP signaling,attenuates renal fibrotic disease. Nat Med 2005; 11: 387-393.
121. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E,Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, KalluriR. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med2007; 13: 952-961.
122. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R.BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition andreverses chronic renal injury. Nat Med 2003; 9: 964-968.
123. Zeisberg M, Muller GA, Kalluri R. Are there endogenous molecules that protectkidneys from injury? The case for bone morphogenic protein-7 (BMP-7). Nephrol DialTransplant 2004; 19: 759-761.
124. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets,regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005; 16:251-263.
125. Simic P, Vukicevic S. Bone morphogenetic proteins in development and homeostasisof kidney. Cytokine Growth Factor Rev 2005; 16: 299-308.
126. Simic P, Vukicevic S. Bone morphogenetic proteins: from developmental signals totissue regeneration. Conference on bone morphogenetic proteins. EMBO Rep 2007;8: 327-331.
127. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, Okada H, CarlsonJr W, Bey P, Rusckowski M, Tampe B, Tampe D, Kanasaki K, Zeisberg M, Kalluri R.Activin-like kinase-3 activity is important for kidney regeneration and reversal offibrosis. Nat Med 2012; 18: 396-404.
128. Ka SM, Yeh YC, Huang XR, Chao TK, Hung YJ, Yu CP, Lin TJ, Wu CC, Lan HY, Chen A.Kidney-targeting Smad7 gene transfer inhibits renal TGF-beta/MAD homologue(SMAD) and nuclear factor kappaB (NF-kappaB) signalling pathways, and improvesdiabetic nephropathy in mice. Diabetologia 2012; 55: 509-519.
129. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. Inhibitor ofhematopoietic pluripotent stem cell proliferation: purification and determination of itsstructure. Proc Natl Acad Sci USA 1989; 86: 779-782.
130. Grillon C, Rieger K, Bakala J, Schott D, Morgat JL, Hannappel E, Voelter W, LenfantM. Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis ofthe tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Lett1990; 274: 30-34.
131. Liu JM, Garcia-Alvarez MC, Bignon J, Kusinski M, Kuzdak K, Riches A, Wdzieczak-Bakala J. Overexpression of the natural tetrapeptide acetyl-N-ser-asp-lys-pro derivedfrom thymosin beta4 in neoplastic diseases. Ann NY Acad Sci 2010; 1194: 53-59.
132. Cavasin MA, Rhaleb NE, Yang XP, Carretero OA. Prolyl oligopeptidase is involved inrelease of the antifibrotic peptide Ac-SDKP. Hypertension 2004; 43: 1140-1145.
133. Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, Riley PR.Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization.Nature 2007; 445: 177-182.
134. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, CorvolP, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasmalevel of the natural stem cell regulator N-acetyl-seryl-aspartyl- lysyl-proline. J ClinInvest 1996; 97: 839-844.
135. Kanasaki K, Haneda M, Sugimoto T, Shibuya K, Isono M, Isshiki K, Araki S, Uzu T,Kashiwagi A, Koya D. N-acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis inhuman mesangial cells via up-regulation of cell cycle modulators. Biochem BiophysRes Commun 2006; 342: 758-765.
136. Iwamoto N, Xano HJ, Yoshioka T, Shiraga H, Nitta K, Muraki T, Ito K. Acetylseryl-aspartyl-lysyl-proline is a novel natural cell cycle regulator of renal cells. Life Sci2000; 66: PL221-PL226.
137. Rhaleb NE, Peng H, Harding P, Tayeh M, LaPointe MC, Carretero OA. Effect ofN-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiacfibroblasts. Hypertension 2001; 37: 827-832.
138. Rhaleb NE, Peng H, Yang XP, Liu YH, Mehta D, Ezan E, Carretero OA. Long-termeffect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition inrats with 2-kidney, 1-clip hypertension. Circulation 2001; 103: 3136-3141.
139. Peng H, Carretero OA, Raij L, Yang F, Kapke A, Rhaleb NE. Antifibrotic effects ofN-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salthypertensive rats. Hypertension 2001; 37(Part 2): 794-800.
140. Kanasaki K, Koya D, Sugimoto T, Isono M, Kashiwagi A, Haneda M. N-Acetyl-serylaspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1expression via inhibition of Smad pathway in human mesangial cells. J Am SocNephrol 2003; 14: 863-872.
141. Omata M, Taniguchi H, Koya D, Kanasaki K, Sho R, Kato Y, Kojima R, Haneda M,Inomata N. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renaldysfunction and fibrosis in WKY rats with established anti-glomerular basementmembrane nephritis. J Am Soc Nephrol 2006; 17: 674-685.
142. Lin CX, Rhaleb NE, Yang XP, Liao TD, D'Ambrosio MA, Carretero OA.Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline inangiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 2008; 295:H1253-H1261.